MannKind Expands Executive Leadership Team

MNKD 01.06.2025

Full Press ReleaseSEC FilingsOur MNKD Tweets

About Gravity Analytica

Recent News

  • 01.06.2025 - MannKind Expands Executive Leadership Team
  • 12.20.2024 - Tiago Fauth
  • 12.18.2024 - MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash

Recent Filings

  • 01.06.2025 - 8-K Current report
  • Dominic Marasco, RPh, joins the company as President, Endocrine Business Unit, effectiveJanuary 6, 2025

DANBURY, Conn.andWESTLAKE VILLAGE, Calif.,Jan. 06, 2025(GLOBE NEWSWIRE) --MannKind Corporation(Nasdaq: MNKD), a company focusing on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today thatDominic Marasco, RPh, has joined the company as President, Endocrine Business Unit, effectiveJanuary 6, 2025.

Mr. Marascois a member of MannKind’s executive leadership team and reports toMichael Castagna, PharmD, Chief Executive Officer. “Dominic is an innovative leader recognized for driving strategic growth and operational excellence that will be transformative for our Endocrine Business Unit,” saidDr. Castagna. “As we continue to build upon the positive clinical trial readouts for Afrezza, Dominic’s global experience will be instrumental to our company’s future.”

Mr. MarascojoinsMannKindwith an accomplished track record of more than 25 years of driving commercial success in the biopharma and biotech sectors. He recently held the position of Executive President, Chief Commercial Officer forEnvision Pharma Group, leading its technology and artificial intelligence business units and all commercial operations. Before joining Envision Pharma inFebruary 2023,Mr. Marascowas Chief Commercial Officer atBioAgilytix Labs, Inc.fromDecember 2019untilDecember 2022.

Prior to BioAgilytix, he was EVP, Global Business Development,Commercial GroupatSyneos Healthafter serving in progressive leadership roles at Amgen, Inc. including Head ofU.S.Sales for the Neuroscience Business Unit and before that Global Commercial Head, Amgen Biosimilars.Mr. Marascoalso held successful commercial leadership roles at Sandoz Biopharmaceuticals, aNovartis Company, andQuintiles Transnational Holdings Inc(now IQVIA).

He began his career as a pharmacist before joining Eli Lilly and Company in a sales capacity.Mr. Marascois a graduate of thePhiladelphia College of Pharmacyand an alumnus of the Harvard Business School’s Advanced Management Program.

“The energy behind Afrezza and the momentum of MannKind’s pipeline is inspiring,” said Marasco. “I am excited to work with an innovative team that continues to push the boundaries of what’s possible in endocrine care and help more patients worldwide.”

AboutMannKindMannKind Corporation(Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.

We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.

With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

Please visitmannkindcorp.comto learn more, and follow us onLinkedIn,Facebook,XorInstagram.

Forward-Looking StatementsThis press release contains forward-looking statements about the potential transformation of a business unit that involves risks and uncertainties. Words such as “believes”, “anticipates”, “plans”, “expects”, “intends”, “will”, “goal”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that the products we are commercializing may only achieve a limited degree of commercial success, and other risks detailed in MannKind’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

MANNKIND is a registered trademark of MannKind Corporation.

MannKind Contacts:Media RelationsChristie Iacangelo(818) 292-3500Email: media@mnkd.comInvestor RelationsAna Kapor(818) 661-5000Email: ir@mnkd.com

Primary Logo

Source: MannKind

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com